IDEAYA Biosciences Stock Price - IDYA

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
IDEAYA Biosciences Inc IDYA NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.29 -3.98% 6.99 6.91 7.34 7.34 7.28 20:00:00
Bid Price Ask Price Spread Spread % News
4.25 7.96 3.71 46.61% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
349 28,714 $ 7.13 $ 204,706 40,819 2.95 - 16.75
Last Trade Time Type Quantity Stock Price Currency
16:00:00 1,075 $ 6.99 USD

IDEAYA Biosciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 142.59M 20.40M 19.49M $ - $ - -2.54 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 6.00 4.50%

more financials information »

IDEAYA Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IDYA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week6.748.486.55017.6248,5520.253.71%
1 Month5.208.484.93016.8444,6651.7934.42%
3 Months6.838.482.955.0847,9000.162.34%
6 Months6.8011.452.956.6845,5050.192.79%
1 Year14.0016.752.957.8948,579-7.01-50.07%
3 Years14.0016.752.957.8948,579-7.01-50.07%
5 Years14.0016.752.957.8948,579-7.01-50.07%

IDEAYA Biosciences Description

IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.